Expression of P504s and claudin-4 in prostate cancer and prognostic value of their combined detection

• Main Authors: BI Gang, MAO Chengyi, JIANG Jun, ZHANG Yao, ZHANG Jun, LONG Yin
• Format: Article
• Language: zho
• Published: Editorial Office of Journal of Third Military Medical University 2019-11-01
• Series: Di-san junyi daxue xuebao
• Subjects: prostate cancer; p504s; claudin-4; tissue microarray; immunohistochemistry; prognosis
• Online Access: http://aammt.tmmu.edu.cn/Upload/rhtml/201906084.htm

Objective To investigate the expression of P504s and claudin-4 in prostate cancer tissues and assess the value of their combined detection in prognostic evaluation of prostate cancer. Methods We analyzed a total of 154 surgical specimens or biopsy samples of prostate tissues collected between January, 2013 and July, 2015 in the pathological tissue bank of our hospital. These specimens, which consisted of 84 prostate cancer tissues from patients aged 52 to 83 years (mean 70.9±7.3 years) and 70 benign prostatic hyperplasia tissues from patients aged 51 to 85 years (mean 68.2±7.4 years), were used to construct 60-dot matrix paraffin tissue chips for detection of P504s and claudin-4 proteins using immunohistochemistry with SP method. The correlation of P504s and claudin-4 expression with the prognosis of the patients with prostate cancer was analyzed. Results The positive expression rates of P504s and claudin-4 protein were significantly lower in benign prostatic hyperplasia tissues than in prostate cancer tissues (P < 0.01). The tissue microarray data did not reveal significant difference in the positive expression rate of P504s in prostate cancer tissues with different Gleason scores or in different stages. The positive expression rates of claudin-4 protein was significantly lower in prostate cancer with a Gleason score ≤6 than in that with a score ≥7 (60.98% vs 74.42%, P < 0.05), and was also lower in prostate cancer in T2a stage or lower than that in T2b stage or higher (55.26% vs 78.26%, P < 0.01). Conclusion Abnormal expression of P504s and claudin-4 proteins may be related with the occurrence and progression of prostate cancer, and prostate cancer with a higher level of malignancy expresses higher levels of claudin-4. Combined detection of P504s and claudin-4 can improve the detection rate of prostate cancer and can be of value in prognostic evaluation of the patients.